Early B-cell factors involve in the tumorigenesis and predict the overall survival of gastric cancer
Open Access
- 28 June 2021
- journal article
- research article
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 41 (7)
Abstract
Gastric cancer (GC) is a heavy health burden around the world, which is the fifth most frequent tumor and leads to the third most common cancer-related deaths. It is urgent to identify prognostic markers as the guideline for personalized treatment and follow-up. We accessed the prognostic value of Early B-cell factors (EBFs) in GC. A total of 415 GC tissues and 34 normal tissues from The Cancer Genome Atlas Stomach Adenocarcinoma (TCGA-STAD) cohort, 616 external patients from GSE15459, GSE22377, GSE51105, GSE62245 were enrolled for analysis. Univariate and multivariate Cox regression analyses were employed to evaluate the sole and integrative prognostic value of EBFs, respectively. Genetic alterations, DNA methylation of EBFs were also evaluated, as well as the involved signaling pathways. We revealed that increased EBFs associated with the poor prognosis of GC patients, the prognostic model was established in TCGA-STAD cohort, and validated in Gene Expression Omnibus (GEO) cohorts, with effectiveness in both HER2 positive and negative patients. DNA methylation was involved in the impact on prognosis. Cell cycle, immune-associated, and MAPK pathways were influenced by EBFs. Anti-CTLA4 immunotherapy is more suitable for EBFs determining high-risk groups, but not anti-PD-1/PD-L1 therapy. 5-Fluorouracil, methotrexate, vorinostat are suitable to inhibit the function of EBFs. Our new findings provide novel insight into the prediction of prognosis and clinical treatment of GC patients based on EBFs.Keywords
This publication has 58 references indexed in Scilit:
- GSVA: gene set variation analysis for microarray and RNA-Seq dataBMC Bioinformatics, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Aberrant DNA methylation and tumor suppressive activity of the EBF3 gene in gastric carcinomaInternational Journal of Cancer, 2011
- A Genome-wide screen identifies frequently methylated genes in haematological and epithelial cancersMolecular Cancer, 2010
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- Increased Expression of Early B-cell Factor 3 in Human Hepatocellular Carcinoma and the Effect of EBF3 Overexpression on HepG2 Cell CyclingLaboratory Medicine, 2009
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic targetAnnals of Oncology, 2008
- Transcription factor EBF restricts alternative lineage options and promotes B cell fate commitment independently of Pax5Nature Immunology, 2008
- Interleukin-7 is necessary to maintain the B cell potential in common lymphoid progenitorsJournal of Experimental Medicine, 2005
- Cloning of a Novel Olf-1/EBF-like Gene, O/E-4, by Degenerate Oligo-based Direct SelectionMolecular and Cellular Neuroscience, 2002